TY - JOUR
T1 - Comparison of single- and multiple-dose cefazolin as prophylaxis for transurethral enucleation of prostate
T2 - A multicenter, prospective, randomized controlled trial by the Japanese Research Group for Urinary Tract Infection
AU - Togo, Yoshikazu
AU - Fukui, Koji
AU - Ueda, Yasuo
AU - Kanamaru, Sojun
AU - Shimizu, Yosuke
AU - Wada, Koichiro
AU - Sadahira, Takuya
AU - Yamada, Yusuke
AU - Matsumoto, Masahiro
AU - Hamasuna, Ryoichi
AU - Ishikawa, Kiyohito
AU - Takai, Manabu
AU - Maekawa, Yuka
AU - Yasuda, Mitsuru
AU - Kokura, Koji
AU - Kondoh, Nobuyuki
AU - Takiuchi, Hidekazu
AU - Yamamoto, Shingo
N1 - Publisher Copyright:
© 2020 The Japanese Urological Association
PY - 2020/3/1
Y1 - 2020/3/1
N2 - Objectives: To compare the optimal administration period of antimicrobial prophylaxis in patients undergoing transurethral enucleation of the prostate for benign prostatic hyperplasia. Methods: We carried out a randomized controlled trial to compare the differences in incidence of perioperative genitourinary tract infection between single and multiple (3 days) administrations of cefazolin for transurethral enucleation of the prostate in benign prostatic hyperplasia patients without pyuria or bacteriuria between January 2015 and December 2018. Results: This multicenter randomized controlled trial included 203 patients who underwent a transurethral enucleation of the prostate procedure. All received antimicrobial prophylaxis, and were randomized into those who received single-dose (n = 101) or multiple-dose (n = 102) therapy. The rate of genitourinary tract infection after transurethral enucleation of the prostate for all patients was 1.5%, whereas that in the single-dose group was 1.0% and in the multiple-dose group was 2.0%, which were not significantly different (P = 1.00). Conclusions: A single dose of antimicrobial prophylaxis as a prophylactic antibacterial drug is sufficient for patients undergoing transurethral enucleation of the prostate who do not have presurgical pyuria or bacteriuria.
AB - Objectives: To compare the optimal administration period of antimicrobial prophylaxis in patients undergoing transurethral enucleation of the prostate for benign prostatic hyperplasia. Methods: We carried out a randomized controlled trial to compare the differences in incidence of perioperative genitourinary tract infection between single and multiple (3 days) administrations of cefazolin for transurethral enucleation of the prostate in benign prostatic hyperplasia patients without pyuria or bacteriuria between January 2015 and December 2018. Results: This multicenter randomized controlled trial included 203 patients who underwent a transurethral enucleation of the prostate procedure. All received antimicrobial prophylaxis, and were randomized into those who received single-dose (n = 101) or multiple-dose (n = 102) therapy. The rate of genitourinary tract infection after transurethral enucleation of the prostate for all patients was 1.5%, whereas that in the single-dose group was 1.0% and in the multiple-dose group was 2.0%, which were not significantly different (P = 1.00). Conclusions: A single dose of antimicrobial prophylaxis as a prophylactic antibacterial drug is sufficient for patients undergoing transurethral enucleation of the prostate who do not have presurgical pyuria or bacteriuria.
KW - antimicrobial prophylaxis
KW - benign prostatic hyperplasia
KW - optimal administration period
KW - randomized controlled trial
KW - transurethral enucleation of the prostate
UR - http://www.scopus.com/inward/record.url?scp=85078747266&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078747266&partnerID=8YFLogxK
U2 - 10.1111/iju.14181
DO - 10.1111/iju.14181
M3 - Article
C2 - 31965649
AN - SCOPUS:85078747266
SN - 0919-8172
VL - 27
SP - 244
EP - 248
JO - International Journal of Urology
JF - International Journal of Urology
IS - 3
ER -